Wegovy Dosing, Explained: How the Label Escalation Works

——————————————————————————–

The first Wegovy pen delivers a small fraction of the eventual maintenance dose, and that is deliberate. Here is the most important thing to understand up front: Wegovy dosing is not a plan you set for yourself. Wegovy (semaglutide) is a prescription-only medicine, and every step of the dose — when to start, whether to move up, whether to hold, and where to settle — is chosen and adjusted by your prescriber based on how your body responds. This guide explains, in general terms, how the FDA label’s gradual escalation is designed to work, why it climbs slowly, how the newer oral version differs, and the safety rules that matter most. It is not a self-dosing schedule, and nothing here should be used to escalate, hold, or restart on your own.

How Wegovy Works on a Weekly Schedule

The original Wegovy is a once-weekly subcutaneous injection given in a single-dose prefilled pen. Per the FDA prescribing information, each dose is injected into the abdomen, thigh, or upper arm. Semaglutide has a long half-life of roughly seven days, which is why weekly dosing can maintain relatively steady blood levels rather than sharp peaks and troughs. In late 2025 the FDA also approved a once-daily oral Wegovy (tablets) — a separate product covered further down that has its own, different dosing and should never be confused with the weekly pen.

Your prescriber will tell you which day to inject; the general principle on the label is consistency — the same day each week, as closely as possible. Rotating injection sites helps reduce skin and tissue changes from repeated same-spot injections. If any of this is unclear from your own instructions, ask the prescribing office or your pharmacist rather than guessing.

How the Label’s Dose Escalation Is Designed

Rather than starting at the full amount, the FDA label describes a gradual escalation that begins with a low starting dose and steps up in stages over several months, with the injection reaching a standard maintenance dose of 2.4 mg once weekly. The whole point of stepping up slowly is tolerability: starting low and increasing gradually is intended to reduce nausea and other gastrointestinal effects that are most likely when the dose changes. An intermediate step was built into the schedule specifically to smooth the jump toward the maintenance dose, because larger single increases produced more side effects in trials.

Important framing: those figures describe what the label lays out, which your prescriber sets and adjusts — they are not a ladder for you to follow on your own. The label’s timing for each step is a minimum interval, not a target to rush. Your prescriber decides when (or whether) to move up, and many clinicians deliberately hold patients at a lower dose longer than the minimum when someone is still adapting. In the STEP 1 trial, participants who reached and stayed on the 2.4 mg maintenance dose lost an average of about 15 percent of their baseline body weight over 68 weeks, alongside diet and activity — but that result came from a supervised, individualized escalation, not a fixed self-managed plan.

In 2025 the FDA also approved a higher-dose injection, Wegovy HD (semaglutide 7.2 mg), as an option for some people who tolerate 2.4 mg but need additional treatment. Whether a higher maintenance dose is appropriate is entirely a prescriber’s decision.

Why Your Prescriber Sets Every Step

There is no universal “right week” to move up, because tolerance differs from person to person. A prescriber weighs how your GI symptoms are settling, whether you are eating and hydrating normally, your other medical conditions and medications, and your overall response. From those factors they decide whether to advance, stay put, or step back — which is exactly why this article does not hand you a week-by-week milligram plan to copy.

Telehealth and in-person prescribers routinely hold patients at a lower dose longer than the label’s minimum when patients are still adjusting, and the overall weight-loss arc is usually not harmed by a slower, better-tolerated schedule. If a dose increase feels premature, that is a conversation to have with your prescriber — not a change to make yourself. Never escalate your own dose, and never try to “catch up” by taking extra.

When a Prescriber May Hold or Step Back

If nausea, vomiting, or significant constipation are still prominent, a prescriber may keep you at your current dose longer before considering any increase. If side effects worsen after a step up, a clinician may return you to the previous level for a while before deciding whether to try again. Unusually rapid weight loss can also prompt a prescriber to hold, because losing weight very quickly can contribute to muscle loss, fatigue, and gallbladder problems. These are all clinical judgments your prescriber makes with you — not adjustments to attempt on your own.

Missed Doses

The FDA label includes general guidance for a missed weekly injection: if your next scheduled dose is far enough away, you may take the missed dose when you remember, and if it is close to the next dose, you skip the missed one and resume your usual schedule — you never take two doses close together to make up for a missed one, because that amplifies side effects. Because the exact timing rules and any longer gap depend on your situation, the safest move if you are unsure is to contact your prescriber or pharmacist. After a longer interruption, tolerance to the medication fades, and a prescriber will decide whether you can resume where you left off or need to restart at a lower dose. Do not make that call yourself. For coverage-related pauses, see is Wegovy covered by insurance.

Managing Side Effects

Nausea is the most common complaint and tends to be worse in the days after a dose change. General comfort measures that clinicians often suggest include smaller, more frequent meals, avoiding very greasy or high-fat foods, staying upright for a while after eating, and sipping fluids through the day. Constipation is also common as digestion slows; adequate fiber, hydration, and gentle activity like walking are typical first steps, and your prescriber can advise on whether any laxative is appropriate for you. Gallbladder problems are less common but can be serious — severe pain in the upper-right abdomen warrants prompt medical attention. Semaglutide also carries FDA warnings, including a boxed warning about thyroid C-cell tumors seen in rodents; it is not for people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and pancreatitis and other serious effects are described in the label. Review the full warnings with your prescriber.

Do Not Use Compounded or Counterfeit Semaglutide

This is a critical 2026 safety point. Use only FDA-approved Wegovy obtained through a legitimate pharmacy with a valid prescription. The FDA-recognized semaglutide shortage was resolved in February 2025, which ended the routine legal pathway for pharmacies to compound copies, and in September 2025 the FDA sent warning letters to dozens of companies making or marketing compounded GLP-1 products. Compounded “semaglutide,” research-chemical vials, and counterfeit pens are not FDA-approved and have not been reviewed for safety, effectiveness, or quality; dosing errors and contamination have caused harm. Do not buy semaglutide outside the regulated supply chain, do not split or share pens, and do not use a product just because it is cheaper or easier to get.

The New Oral Wegovy Is a Different Product

On December 22, 2025, the FDA approved a once-daily oral Wegovy (semaglutide tablets) for chronic weight management in adults, with a US launch in early 2026. It is a distinct product from the weekly injection, with its own strengths and its own separate escalation to a much higher milligram maintenance tablet — the tablet numbers are not comparable to the injection numbers and cannot be swapped one for one. If you are prescribed the oral form, follow those specific instructions exactly; do not assume anything about the pill from what you know about the pen, and vice versa.

Maintenance and Staying on Treatment

Not everyone ends up at the maximum injection dose; some people do well on a lower maintenance dose, and where you settle is a shared decision with your prescriber. Obesity is considered a chronic condition by the CDC, and stopping the medication often leads to weight regain over time, so many people stay on maintenance treatment long-term under ongoing medical supervision. See our Wegovy doses overview for more on the dose levels themselves.

Frequently Asked Questions

Can I speed up my Wegovy titration to lose weight faster?

No — and you should never adjust your dose on your own. The gradual escalation exists to reduce side effects, and moving faster tends to cause more nausea and vomiting without improving long-term results. Any change to your schedule is your prescriber’s decision.

Do I have to stay at each dose for a set number of weeks?

The label lists a minimum interval before a dose can be increased, but staying longer is common and often better tolerated. Your prescriber decides when, or whether, to advance based on your symptoms and response — it is not a fixed timetable you manage yourself.

What if I accidentally take too much or double up?

Contact your prescriber, and for a suspected overdose call Poison Control at 1-800-222-1222 (free, 24/7) or 911. Taking more than prescribed can cause severe nausea and vomiting and does not speed progress.

Is the Wegovy pill the same as the injection?

No. The oral Wegovy tablet approved in December 2025 is a separate product with different strengths and its own dosing. The milligram numbers are not interchangeable with the injection, so follow the exact instructions for whichever one you are prescribed.

How long does Wegovy stay in my system?

Because semaglutide has a long half-life, it clears slowly — roughly a month or more after the last injection. This is one reason stopping does not cause abrupt withdrawal, though appetite and weight effects fade as levels fall.

The Bottom Line

Effective Wegovy dosing is patient, individualized, and prescriber-directed. The FDA label’s gradual escalation is designed to start low and step up slowly to limit side effects — but the actual pace, holds, and any dose changes are decisions your prescriber makes with you, not a ladder to follow on your own. Never escalate, split, share, or improvise doses, avoid unregulated or counterfeit semaglutide entirely, and keep the oral and injectable products straight. If you are still weighing cost and access, the healthcare costs pillar and Wegovy cost guide can help you plan.